Literature DB >> 7907625

An outbreak of multiresistant Klebsiella in a neonatal intensive care unit.

O Reish1, S Ashkenazi, N Naor, Z Samra, P Merlob.   

Abstract

An outbreak of multiresistant Klebsiella pneumoniae occurring in a neonatal intensive care unit is described. All infections developed at least 5 days after admission to the unit (range, 5-40 days). Four infants had septicaemia and one had urinary tract infection. Three of the infected infants died. All klebsiella isolates were resistant to ampicillin, cefotaxime, cefuroxime, co-amoxiclav, mezlocillin, chloramphenicol, gentamicin, and ceftazidime (except in two); all were susceptible to imipenem, amikacin and quinolones. An extensive case-control study identified the following significant risk factors for colonization: prematurity; presence of indwelling catheters; previous antibiotic treatment; and parenteral nutrition. The outbreak was controlled with re-emphasis on strict handwashing practices, cohorting, closure of the unit to outborn admissions, and changing the regimen of empirical antibiotic therapy. Physicians should be aware of multiresistant Klebsiella spp. and change treatment whenever clinically indicated, even before culture results are available.

Entities:  

Mesh:

Year:  1993        PMID: 7907625     DOI: 10.1016/0195-6701(93)90115-g

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  13 in total

1.  Vancomycin-resistant enterococci in intensive-care hospital settings: transmission dynamics, persistence, and the impact of infection control programs.

Authors:  D J Austin; M J Bonten; R A Weinstein; S Slaughter; R M Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

2.  Large oligoclonal outbreak due to Klebsiella pneumoniae ST14 and ST26 producing the FOX-7 AmpC β-lactamase in a neonatal intensive care unit.

Authors:  Fabio Arena; Tommaso Giani; Elisa Becucci; Viola Conte; Giacomo Zanelli; Marco Maria D'Andrea; Giuseppe Buonocore; Franco Bagnoli; Alessandra Zanchi; Francesca Montagnani; Gian Maria Rossolini
Journal:  J Clin Microbiol       Date:  2013-10-02       Impact factor: 5.948

Review 3.  Clinical, bacteriological, and serological aspects of Klebsiella infections and their spondylarthropathic sequelae.

Authors:  H Sahly; R Podschun
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

4.  Neonatal Klebsiella pneumonia sepsis and imipenem/cilastatin.

Authors:  R Oral; M Akisü; N Kültürsay; F Vardar; N Tansuğ
Journal:  Indian J Pediatr       Date:  1998 Jan-Feb       Impact factor: 1.967

Review 5.  Nosocomial pneumonia in pediatric patients: practical problems and rational solutions.

Authors:  Heather J Zar; Mark F Cotton
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

6.  Successful elimination of extended-spectrum beta-lactamase (ESBL)-producing nosocomial bacteria at a neonatal intensive care unit.

Authors:  Borbála Szél; Zsolt Reiger; Edit Urbán; Andrea Lázár; Krisztina Mader; Ivelina Damjanova; Kamilla Nagy; Gyula Tálosi
Journal:  World J Pediatr       Date:  2016-11-23       Impact factor: 2.764

7.  Meningitis caused by Escherichia coli producing TEM-52 extended-spectrum beta-lactamase within an extensive outbreak in a neonatal ward: epidemiological investigation and characterization of the strain.

Authors:  Didier Moissenet; Béatrice Salauze; Olivier Clermont; Edouard Bingen; Guillaume Arlet; Erick Denamur; Audrey Mérens; Delphine Mitanchez; Hoang Vu-Thien
Journal:  J Clin Microbiol       Date:  2010-06-02       Impact factor: 5.948

8.  Inhibition of aminoglycoside 6'-N-acetyltransferase type Ib-mediated amikacin resistance by antisense oligodeoxynucleotides.

Authors:  Renee Sarno; Hongphuc Ha; Natalia Weinsetel; Marcelo E Tolmasky
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 9.  Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors.

Authors:  R Podschun; U Ullmann
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132

Review 10.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C P Rains; H M Bryson; D H Peters
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.